LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM) today announced that it will be presenting at the 11th annual LD Micro Main Event on Thursday, December 6th at 9:30 AM PST, 12:30 PM EST. Dr. Alan Joslyn, Chief Executive Officer of Oragenics, Inc. will be presenting and meeting with investors.
"Internally, our entire year leads up to the Main Event. It has become the 'one thing' everyone in the small and micro-cap world knows us for. Also, free mints" stated Chris Lahiji, while enjoying a mint. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the most interesting businesses in the world to our ever growing community."
The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals.
About Oragenics, Inc.
We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allows Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.
For more information about Oragenics, please visit www.oragenics.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.
What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
Michael Sullivan, 813-286-7900
Chief Financial Officer
John Marco, 310-819-2948
Jules Abraham, 917-885-7378
SOURCE: Oragenics, Inc.